4/12
08:24 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $43.00 to $45.00. They now have an "outperform" rating on the stock.
Medium
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $43.00 to $45.00. They now have an "outperform" rating on the stock.
4/12
04:33 am
rvmd
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity [Seeking Alpha]
Medium
Report
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity [Seeking Alpha]
4/10
10:09 am
rvmd
Aptevo Therapeutics, TRACON Pharmaceuticals, BioSig Technologies among healthcare movers [Seeking Alpha]
Low
Report
Aptevo Therapeutics, TRACON Pharmaceuticals, BioSig Technologies among healthcare movers [Seeking Alpha]
4/10
08:55 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $48.00 price target on the stock, up previously from $36.00.
Medium
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $48.00 price target on the stock, up previously from $36.00.
4/9
03:39 pm
rvmd
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins [Yahoo! Finance]
Low
Report
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins [Yahoo! Finance]
4/9
03:34 pm
rvmd
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Low
Report
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
4/8
11:45 am
rvmd
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins [Yahoo! Finance]
Low
Report
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins [Yahoo! Finance]
4/8
11:36 am
rvmd
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Low
Report
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
4/8
08:10 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
4/4
04:05 pm
rvmd
Revolution Medicines to Participate in Upcoming Investor Conferences
Medium
Report
Revolution Medicines to Participate in Upcoming Investor Conferences
4/4
07:07 am
rvmd
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs [Yahoo! Finance]
Low
Report
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs [Yahoo! Finance]
3/28
04:19 pm
rvmd
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
3/28
04:05 pm
rvmd
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
Low
Report
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
3/11
08:12 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $43.00 price target on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $43.00 price target on the stock.
2/28
10:46 am
rvmd
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
06:51 am
rvmd
Revolution Medicines Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Revolution Medicines Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
2/27
09:00 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Wedbush from $41.00 to $42.00. They now have an "outperform" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Wedbush from $41.00 to $42.00. They now have an "outperform" rating on the stock.
2/26
04:42 pm
rvmd
Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress [Yahoo! Finance]
Low
Report
Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress [Yahoo! Finance]
2/26
04:09 pm
rvmd
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress [Yahoo! Finance]
Medium
Report
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress [Yahoo! Finance]
2/26
04:05 pm
rvmd
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
Medium
Report
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
2/20
04:05 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Neutral
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
2/1
04:20 pm
rvmd
Revolution Medicines to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Revolution Medicines to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/1
04:05 pm
rvmd
Revolution Medicines to Participate in Upcoming Investor Conferences
Low
Report
Revolution Medicines to Participate in Upcoming Investor Conferences